Navigation

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)

Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer

Status: History
Expected date of issue: April 2011
Referral date: November 2008
Process: STA
Topic area:
  • Cancer
  • Respiratory
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Helen Tucker
Communications manager: Alice Law
Project manager: Kate Moore
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 19 January 2010
1st appraisal committee meeting: 27 April 2010
2nd appraisal committee meeting 27 October 2010
3rd appraisal committee meeting: 25 January 2011
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Roche (erlotinib)

Patient/carer groups

  • Macmillan Cancer Support
  • Roy Castle Lung Cancer Foundation

Professional groups

  • British Thoracic Society
  • Cancer Research UK
  • National Lung Cancer Forum for Nurses
  • Royal College of Nursing
  • Royal College of Physicians’ Intercollegiate Lung Cancer Group
  • United Kingdom Oncology Nursing Society

Others

  • Cornwall and the Isles of Scilly PCT
  • Department of Health
  • Dudley PCT
  • Welsh Assembly Government

General

  • NHS Quality Improvement Scotland

Comparator manufacturers

  • Eli Lilly & Co. (pemetrexed)

Relevant research groups

  • British Thoracic Oncology Group

Evidence Review Group

  • Liverpool Reviews and Implementation Group (LRIG)
  • National Institute for Health Research Health Technology Assessment Programme

Associated Guideline Groups

  • National Collaborating Centre for Cancer

Associated Public Health Groups

  • None

Top


 

Project history

Date Update
21 July 2010 The discussion of erlotinib monotherapy for the maintenance treatment of non small cell lung cancer at the Appraisal Committee meeting, planned for 27 July 2010, will be postponed. The manufacturer of erlotinib, Roche, asked for the opportunity to submit an extensive amount of new evidence that will require additional time to be reviewed by the Evidence Review Group. This new evidence is related to receipt of the final marketing authorisation for erlotinib in this indication and the publication of related NICE guidance.

A new committee date will announced in due course.
28 May 2010 The Appraisal Committee met to discuss the STA of erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer on 27 April 2010.

The manufacturer included a proposed Patient Access Scheme (PAS) in their evidence submission. The Department of Health advised that it would be reasonable for the Appraisal Committee to consider the proposed PAS at that meeting, however it was not able to confirm the final status of the PAS.  NICE can only issue the ACD once formal ministerial sign off has been received. Therefore the ACD cannot yet be issued and erlotinib will no longer be discussed by the Appraisal Committee on 23 June 2010. We will let you know as soon as possible when we can proceed to ACD consultation and apologise that we cannot provide more clarity about the future timelines for this appraisal.
15 May 2009 The above appraisal has been rescheduled to align with latest regulatory expectations. We expect a new submission date in November 2009.
Top


 

Key documents

This page was last updated: 29 June 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.